New FDA approved nasal spray esketamine can relieve depression, reports a new study. The findings of the study are published in the American Journal of Psychiatry
A new nasal spray has been found effective in treating people with depression who are often unable to relieve their symptoms despite trying other anti-depressants, says a study.
Depression Symptom Evaluation
Depression occurs due to alterations in the levels of neurotransmitters in the brain.
Advertisement
‘Are you suffering from depression? Don’t worry, a new FDA approved esketamine nasal spray can help you fight depression effectively.’
Read More..
Tweet it Now
Read More..
The study published in the American Journal of Psychiatry is one of the key findings that led to the recent US Food and Drug Administration (FDA) approval of esketamine nasal spray, in conjunction with an oral antidepressant, for use in people with treatment-resistant depression.
"This trial of esketamine was one of the pivotal trials in the FDA's review of this treatment for patients with treatment-resistant depression. Not only was adjunctive esketamine therapy effective, the improvement was evident within the first 24 hours," said Michael Thase, Professor at the University of Pennsylvania in the US.
![Holistic Management for Depression]( "Holistic Management for Depression")
Depression is a common disorder and many worldwide suffer from depression. Early recognition of symptoms and signs of depression can help in taking a holistic approach to the management of depression.
"The novel mechanism of action of esketamine, coupled with the rapidity of benefit, underpin just how important this development is for patients with difficult to treat depression," Thase said.
The study was conducted at 39 outpatient centres from August 2015 to June 2017 and involved nearly 200 adults with moderate to severe depression and a history of not responding to at least two antidepressants.
During the research, participants were randomly assigned to one of two groups. One group was switched from their current treatment to esketamine nasal spray (56 or 84 mg twice weekly) plus a newly initiated antidepressant.
The other group was switched from their current treatment to a placebo nasal spray in combination with a new antidepressant, said the study.
The improvement in depression among those in the esketamine group was significantly greater than the placebo group on day 28. Similar improvements were seen at earlier points in time, said the study.
Adverse events in the esketamine group generally appeared shortly after taking the medication and resolved by 1.5 hours later while patients were in the clinic.
The most common side effects included dissociation, nausea, vertigo, dysgeusia (distortion of the sense of taste) and dizziness. Seven percent of patients in the esketamine group discontinued the study due to the side effects.
Source: IANS
Holistic Management for Depression
Depression is a common disorder and many worldwide suffer from depression. Early recognition of symptoms and signs of depression can help in taking a holistic approach to the management of depression.
Advertisement
"The novel mechanism of action of esketamine, coupled with the rapidity of benefit, underpin just how important this development is for patients with difficult to treat depression," Thase said.
The study was conducted at 39 outpatient centres from August 2015 to June 2017 and involved nearly 200 adults with moderate to severe depression and a history of not responding to at least two antidepressants.
During the research, participants were randomly assigned to one of two groups. One group was switched from their current treatment to esketamine nasal spray (56 or 84 mg twice weekly) plus a newly initiated antidepressant.
The other group was switched from their current treatment to a placebo nasal spray in combination with a new antidepressant, said the study.
The improvement in depression among those in the esketamine group was significantly greater than the placebo group on day 28. Similar improvements were seen at earlier points in time, said the study.
Adverse events in the esketamine group generally appeared shortly after taking the medication and resolved by 1.5 hours later while patients were in the clinic.
The most common side effects included dissociation, nausea, vertigo, dysgeusia (distortion of the sense of taste) and dizziness. Seven percent of patients in the esketamine group discontinued the study due to the side effects.
Source: IANS
Herbs that Reduce Anxiety and Depression
Read on to find out which herbs and herbal products are useful and effective in treating the chronic and recurring disorders such as anxiety and depression.
Advertisement
 Senior Citizens Get Tech SavvyBy getting tech-savvy, senior citizens are fostering new engagements, bringing in positive change in their attitude, health, fighting depression and improving the quality of their lives. | Advertisement
|
Advertisement
Recommended Reading
Latest Drug News
Addressing the unmet needs of Parkinson's Disease by providing disease-modifying therapies could bring about a major shift in the way that patients are treated.
Microrobots could swirl through a person's blood stream, search for targeted areas to treat for various ailments.
Supplementation with multivitamins is an inexpensive way for older adults to slow down memory loss.
Some people with an aggressive blood cancer called acute myeloid leukemia (AML) may soon have a new drug option called Ivosidenib that blocks the activity of IDH1 gene.
In case of cardiac failure where the ejection fraction is greater than 40%, sacubitril/valsartan can prove to be quite beneficial